<DOC>
	<DOCNO>NCT02879578</DOCNO>
	<brief_summary>Phase 2 , open-label , fixed-dose titration study evaluate safety tolerability NBI-98854 administer daily total 24 week child , adolescent , adult Tourette Syndrome ( TS ) .</brief_summary>
	<brief_title>Safety Tolerability Study NBI-98854 Treatment Subjects With Tourette Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>Have participate complete NBI988541501 ( TForce Green ) NBI988541505 ( TForward ) Phase 2 study Have clinical diagnosis Tourette Syndrome ( TS ) If use maintenance medication ( ) TS TS spectrum diagnosis ( e.g . obsessivecompulsive disorder [ OCD ] , AttentionDeficit Hyperactivity Disorder [ ADHD ] ) , stable dos Subjects childbearing potential practice total abstinence must agree use hormonal two form nonhormonal contraception ( dual contraception ) consistently screen , treatment followup period study Adolescent adult subject ( 12 64 year age ) must negative urine drug screen amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , cannabinoids negative alcohol screen . Subjects stable dos prescribe supervise ( need ) benzodiazepine , opiate , psychostimulants ( subject comorbid ADHD ) allow participate study Be good general health Have active , clinically significant unstable medical condition within 1 month prior screen Have know history long QT syndrome cardiac arrhythmia Have know history neuroleptic malignant syndrome Have cancer diagnosis within 3 year prior screen ( exception allow ) Have blood loss ≥250 mL donate blood within 56 day prior screen ( subject 6 17 year age ) ; blood loss ≥550 mL donate blood within 30 day prior screen ( subject 18 64 year age ) Have know history substance dependence , substance ( drug ) alcohol abuse Have significant risk suicidal violent behavior Have initiate Comprehensive Behavioral Intervention Tics ( CBIT ) screen period baseline plan initiate CBIT study Have receive investigational drug within 30 day screen plan use investigational drug ( NBI98854 ) study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>